Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model

Tivozanib is a triple vascular endothelial growth factor receptor inhibitor, recently approved for the treatment of refractory advanced renal cell carcinoma. Clinical studies showed that around 46% of patients who received tivozanib suffer from hypertension in all grades. Thus, the present study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Alanazi, Wael A., Alanazi, Abdulrahman S., El-Nagar, Doaa M., Aljuraybah, Abdullah M., Alsanea, Sary, Alharbi, Metab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959867/
https://www.ncbi.nlm.nih.gov/pubmed/37259438
http://dx.doi.org/10.3390/ph16020295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959867/
https://www.ncbi.nlm.nih.gov/pubmed/37259438
http://dx.doi.org/10.3390/ph16020295

Ejemplares similares